[ Back to EurekAlert! ] Public release date: 5-Sep-2013
[ | E-mail Share Share ]

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Some immune cells appear to aid cancer cell growth, U-M study finds

Cells could provide target for potential cancer therapies

IMAGE: Compared to control (left), immune cells (right) promoted tumor sphere formation, an indication of cancer stemness.

Click here for more information.

ANN ARBOR, Mich. The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

A new study from researchers at the University of Michigan Comprehensive Cancer Center found that these cells, called myeloid derived suppressor cells, provide a niche where the cancer stem cells survive.

Cancer stem cells are thought to be resistant to current chemotherapy and radiation treatments, and researchers believe that killing the cancer stem cells is crucial for eliminating cancer.

At the same time that these immune cells help the cancer, they also are suppressing the immune system.

"This cell and its mechanisms are not good for your body and it helps the cancer by allowing the stem cells to thrive. If we can identify a therapy that targets this, we take away the immune suppression and the support for cancer stem cells. Essentially, we kill two birds with one stone," says senior study author Weiping Zou, M.D., Ph.D., Charles B. de Nancrede Professor of surgery, immunology and biology at the University of Michigan Medical School.

The researchers believe the immune cells give the cancer cells their "stemness" those properties that allow the cells to be so lethal and that without this immune cell, the cancer stem cells may not efficiently progress.

The study, which was led by Tracy X. Cui, Ph.D., and Ilona Kryczek, Ph.D., looked at cells from the most common and lethal type of ovarian cancer, a disease in which patients often become resistant to chemotherapy, causing the cancer to return.

Targeting the immune system for cancer treatment, called immunotherapy, has been well-received with many potential therapeutics currently being tested in clinical trials for a variety of cancer types. The U-M team is a worldwide leader in the field of tumor immunology.

###

Additional authors: Other contributors are Lili Zhao, Ende Zhao, Rork Kuick, Michael H. Roh, Linda Vatan, Wojciech Szeliga, Yujun Mao, Dafydd G. Thomas, Max S. Wicha, Kathleen Cho, Thomas Giordano, and J. Rebecca Liu, all from the University of Michigan; and Jan Kotarski and Rafal Tarkowski from Medical University in Lublin, Poland.

Ovarian cancer statistics: 22,240 Americans will be diagnosed with ovarian cancer this year and 14,030 will die from the disease, according to the American Cancer Society

Funding: National Institutes of Health National Cancer Institute grants CA123088, CA099985, CA156685, CA171306 and 5P30-CA46592; the Ovarian Cancer Research Fund, and the Marsha Rivkin Center for Ovarian Cancer Research

Disclosure: None

Reference: Immunity, Vol. 39, No. 3, Sept. 19, 2013

Resources:

U-M Cancer AnswerLine, 800-865-1125

U-M Comprehensive Cancer Center, http://www.mcancer.org

Clinical trials at U-M, http://www.mcancer.org/clinicaltrials



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.